Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The B-cell receptor (BCR) specific to Melopsittacus undulatus (budgerigar) feather allergens is a specialized membrane-bound immunoglobulin complex that mediates the recognition of avian proteins by B-lymphocytes [1]. Upon binding to allergens such as budgerigar serum albumin or feather-derived proteins, the BCR triggers intracellular signaling pathways that lead to B-cell proliferation and differentiation into antibody-secreting plasma cells [2]. The soluble form of this receptor, particularly the IgE isotype, plays a critical role in the pathogenesis of avian-related allergies by sensitizing mast cells and basophils [3]. Cross-linking of allergen-specific IgE on these effector cells by inhaled budgerigar antigens results in the immediate release of inflammatory mediators, causing symptoms of allergic rhinitis and asthma [4]. Chronic exposure can also lead to hypersensitivity pneumonitis, or bird fancier's lung, a condition characterized by immune complex-mediated inflammation in the alveoli [1][5]. Therapeutic strategies targeting this system include the monoclonal antibody omalizumab, which binds to soluble IgE and prevents its attachment to high-affinity FcεRI receptors [3]. Allergen-specific immunotherapy is another approach used to desensitize patients by gradually modifying the B-cell response and promoting the production of neutralizing IgG4 antibodies [4]. Clinical management relies on the detection of budgerigar-specific IgE as a biomarker for diagnosis and to guide treatment decisions [2]. Safety concerns in treating these conditions primarily involve the risk of systemic allergic reactions or anaphylaxis during the administration of immunotherapy [4]. Overall, these receptors are central to the transition from allergen exposure to clinical disease in bird-sensitized individuals. [1] StatPearls: Bird Fancier's Lung; [2] UniProt: B cell receptor; [3] PubChem: Omalizumab; [4] AAAAI: Immunotherapy; [5] PubMed: Budgerigar allergens.
Sequestration of soluble IgE to prevent binding to high-affinity FcεRI receptors on mast cells and basophils; induction of immune tolerance through allergen-specific immunotherapy.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell receptor specific to Melopsittacus undulatus feather allergens (BCR-Mel u) (BCR-Mel u).